Demcizumab
Demcizumab
Demcizumab (pronounced as dem-siz-u-mab) is a monoclonal antibody designed for the treatment of cancer. It is developed by OncoMed Pharmaceuticals and is currently in the clinical trial phase.
Etymology
The name "Demcizumab" is derived from the International Nonproprietary Names (INN), where "zu" indicates humanized, "mab" stands for monoclonal antibody, and "demci" is a unique stem.
Mechanism of Action
Demcizumab works by inhibiting the Notch signaling pathway, a system involved in cell communication that plays a crucial role in cell proliferation and survival. By blocking this pathway, demcizumab can potentially stop or slow the growth of cancer cells.
Clinical Trials
Demcizumab has been tested in several Phase I and Phase II clinical trials for various types of cancer, including lung cancer, pancreatic cancer, and ovarian cancer. The results of these trials have shown promise, but further research is needed to confirm its efficacy and safety.
Related Terms
External links
- Medical encyclopedia article on Demcizumab
- Wikipedia's article - Demcizumab
This WikiMD dictionary article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski